Alpha-7 nicotinic acetylcholine receptor: targeting the interplay between inflammation, renin-angiotensin aldosterone system, and nervous system for the novel treatment of heart failure

Read full text Summarise with VIRAT
Authors: Jordan Swiderski, Laura Kate Gadanec, Stephen Hearth, Benjamin Darcy Rowlands, Andrew James Murphy, Vasso Apostolopoulos, Anthony Zulli
Cited by: 0
References: 245

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The incidence and prevalence of heart failure (HF) with preserved ejection fraction (HFpEF) continue to rise, yet evidence-based therapy remains limited. Due to the complexity of HFpEF pathology, traditional HF medication has shown inconsistent efficacy in improving clinical outcomes and reducing morbidity. Therefore, highlighting the urgent need for novel interventions. The αlpha-7 nicotinic acetylcholine receptor (α7nAChR) is a central mediator of the cholinergic anti-inflammatory pathway and has emerged as a promising therapeutic target in various conditions, such as sepsis, arthritis, metabolic dysfunction, and atherosclerosis. This review aims to examine the emerging therapeutic potential of α7nAChR in HF and HFpEF pathology, focusing on its protective role in modulating the complex interplay between systemic and cardiovascular inflammation, renin-angiotensin-aldosterone system activation, neurocardiac signaling and metabolic dysfunction.

Fields of Study & Subjects

Heart Failure Treatment and Management Nicotinic Acetylcholine Receptors Study Vagus Nerve Stimulation Research

Publication details

Journal / source
Frontiers in Pharmacology
Volume
17
Pages
1756039–1756039
Publication date
19 March 2026
Language
EN